Share
5,698 Posts.
lightbulb Created with Sketch. 82
clock Created with Sketch.
13/03/19
17:19
Share
Originally posted by borisboy:
↑
very excoited $80 Billion and we will get a big chunk of that The Aytu-SUDA licensing agreement calls for SUDA to lead commercial development and sublicensing efforts for ZolpiMist in major territories outside the United States and Canada, including Europe, Asia, and Latin America. The global sleep aid market is currently estimated at almost $50 billion in annual revenue, and annual revenue is estimated to reach nearly $80 billion in 2022. SUDA has already signed sublicensing agreements in key markets with large, multi-national pharmaceutical companies and has agreements in place in China, Chile, Brazil, and throughout Southeast Asia. Additional sublicensing discussions are ongoing with additional prospective sublicensees for Mexico and other geographies. Josh Disbrow, Aytu BioScience's Chief Executive Officer commented, ''We are pleased to be partnering with SUDA as they develop ZolpiMist commercial opportunities around the world. In a short period of time the SUDA team has entered into several sublicensing arrangements with prominent pharmaceutical companies. As such, we expect to see regulatory clearance in at least one market in the coming year. We thank CEO Stephen Carter and the SUDA team for their partnership and look forward to working with SUDA as they continue their ongoing commercial efforts with ZolpiMist around the world.''
Expand
80 Billion is a heck of a lot of money BB, ànd I don't think it's correct. However even if we could get .01%, that is 100th of 1%, of total revenue, that would equal $8m pa. Not bad.